Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry
Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest ...
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
Dexcom advanced the launch of Stelo, its over-the-counter product for non-insulin type 2 diabetes, pre-diabetes, and ...
DexCom Inc. stock underperforms Thursday when compared to competitors
Shares of DexCom Inc. DXCM shed 9.30% to $61.80 Thursday, on what proved to be an all-around grim trading session for the ...
Medical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt
Despite intensive medtech industry lobbying to secure a carve-out from the Trump administration’s expansive tariffs on all ...
Q4 Earnings Highlights: iRhythm (NASDAQ:IRTC) Vs The Rest Of The Patient Monitoring Stocks
Pioneering the shift from bulky, short-term heart monitors to sleek, wire-free patches, iRhythm Technologies (NASDAQ:IRTC) provides wearable cardiac monitoring devices and AI-powered analysis services ...
DexCom Inc. stock outperforms competitors on strong trading day
DexCom Inc. closed 52.01% short of its 52-week high of $141.99, which the company achieved on April 9th.
Explore more
DexCom (DXCM) Slid on Poor Execution and GLP-1 Drug Disruption Concerns
Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A ...
Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring Systems
Eligible residents living with diabetes in Saskatchewan who rely on any type of insulin may be eligible to receive coverage ...